SENSEONICS HOLDINGS INC
SENSNASDAQTrading Snapshot
- Day Range
- $8.30 – $9.39
- 52-Week Range
- $4.79 – $10.64
- Volume (shares)
- 998,818
- Avg Volume (shares)
- —
- Shares Outstanding
- 52.9M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- $35M
- Last Q Revenue
- $14M
- P/E Ratio
- —
- P/S Ratio
- 10.0x
- EPS (TTM)
- $-2.24
- Dividend Yield
- —
- Dilution (1yr)
- +25.2%
SENSEONICS HOLDINGS INC
SENS
StockOtter · stockotter.spaceAbout SENSEONICS HOLDINGS INC
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics' innovation roadmap, with potential launch in 2028
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitori
Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitorin
Senseonics: Eversense 365 Adoption Has To Earn The Valuation
Senseonics is rated Hold due to positive sales growth, margin improvement, and product differentiation, but with significant adoption and funding risks. SENS's Eversense 365 offers unique implantable CGM technology, but
Bank of America Corp DE Acquires 394,465 Shares of Senseonics Holdings, Inc. Common Stock $SENS
Bank of America Corp DE bought a new position in shares of Senseonics Holdings, Inc. Common Stock (NASDAQ: SENS) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.